Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Proposes QbR for New Drugs to Level the Playing Field for CMC Reviews

This article was originally published in The Gold Sheet

Executive Summary

FDA has proposed to expand the use of question-based review, or QbR, to new drugs as part of its efforts to harmonize new and generic drug chemistry reviews. This reflects the agency’s latest efforts to improve the quality of brand and generic drugs by levying “equal expectations” for both.

You may also be interested in...

FDA Developing Initiatives to Improve Quality of Drug Master Files

The quality of DMFs is expected to improve thanks to a soon to be released question- based review system for DMF holders as well a recently issued draft guidance calling for new procedures for reviewing master files called “completeness assessments,” said a pharmaceutical industry official who was a former team leader in FDA’s Office of Generic Drugs.

FDA Warns Generics Firms About January QbD Deadline for ANDAs

Come January, if there is no quality target product profile (QTPP) in an abbreviated new drug application (ANDA), FDA might not file it, agency officials told a Generic Pharmaceutical Association workshop. Even though quality by design (QbD) remains optional for brand drugs, it will be expected for generics, said Office of Generic Drugs representatives who went on to outline pending question-based-review (QbR) revisions designed to elicit QbD information.

New Jersey OTC Firm Lacked GMP Basics, FDA Warning Letter Says

US FDA warns that Health Pharma USA was shipping product before its quality unit could review and test it.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts